

**Table S5** Cox and Fine and Gray regression analyses of 1-year all-cause and CVD-related mortality with Kaplan–Meier and cumulative incidence function estimates for 1-year mortality (Sensitivity analysis of national cohort with at least 1 HF diagnosis, incident HF population)

	<i>N</i> ( <b>N=282,893</b> )	<b>1-year All-cause mortality<sup>a</sup></b>		<b>1-year CVD-related mortality<sup>b</sup></b>	
		<b>Mortality (95%CI)<sup>c</sup></b>	<b>HR (95%CI)<sup>c,d,e</sup></b>	<b>Mortality (95%CI)<sup>f</sup></b>	<b>SHR (95%CI)<sup>e,f,g</sup></b>
<b>Age, years</b>					
<b>18–54</b>	13,759	7.0% (6.5%,7.4%)	1 (reference)	2.5% (2.2%,2.7%)	1 (reference)
<b>55–64</b>	26,155	11.3% (10.9%,11.7%)	1.66 (1.54,1.78)	5.2% (5.0%,5.5%)	2.15 (1.91,2.42)
<b>65–74</b>	52,941	16.8% (16.5%,17.1%)	2.56 (2.40,2.74)	8.1% (7.8%,8.3%)	3.40 (3.05,3.80)
<b>75–84</b>	98,697	26.9% (26.6%,27.2%)	4.39 (4.12,4.68)	14.6% (14.4%,14.8%)	6.40 (5.75,7.13)
<b>≥85</b>	91,341	44.0% (43.7%,44.3%)	8.24 (7.73,8.79)	26.3% (26.0%,26.6%)	12.60 (11.32,14.04)
<b>Sex</b>					
<b>Women</b>	137,831	29.6% (29.4%,29.8%)	1 (reference)	16.8% (16.6%,17.0%)	1 (reference)
<b>Men</b>	145,062	26.7% (26.5%,27.0%)	1.13 (1.11,1.14)	14.6% (14.4%,14.8%)	1.10 (1.08,1.12)
<b>Year of HF diagnosis</b>					
<b>2005</b>	31,217	28.9% (28.4%,29.4%)	1 (reference)	16.9% (16.5%,17.3%)	1 (reference)
<b>2006</b>	31,512	28.5% (28.0%,29.0%)	0.97 (0.94,1.00)	16.7% (16.3%,17.1%)	0.97 (0.94,1.01)
<b>2007</b>	31,484	28.3% (27.8%,28.7%)	0.96 (0.93,0.99)	16.2% (15.8%,16.6%)	0.95 (0.91,0.98)
<b>2008</b>	32,265	28.1% (27.6%,28.6%)	0.95 (0.92,0.98)	15.6% (15.2%,16.0%)	0.90 (0.87,0.94)
<b>2009</b>	31,609	28.0% (27.5%,28.5%)	0.93 (0.90,0.96)	15.4% (15.0%,15.8%)	0.88 (0.84,0.91)
<b>2010</b>	31,840	27.8% (27.3%,28.3%)	0.93 (0.90,0.95)	15.7% (15.3%,16.1%)	0.90 (0.86,0.93)
<b>2011</b>	31,404	27.8% (27.3%,28.3%)	0.93 (0.90,0.96)	15.1% (14.7%,15.5%)	0.86 (0.83,0.89)
<b>2012</b>	31,534	28.2% (27.7%,28.7%)	0.94 (0.91,0.97)	15.2% (14.8%,15.6%)	0.87 (0.83,0.90)
<b>2013</b>	30,028	27.6% (27.1%,28.1%)	0.92 (0.89,0.95)	14.5% (14.1%,14.9%)	0.82 (0.79,0.86)

<sup>a</sup>Patients are censored at emigration (loss to follow-up) and at end of follow-up (31 December 2014).

<sup>b</sup>Patients are censored at emigration, at death due to non-CVD causes and at end of follow-up (31 December 2014).

<sup>c</sup>Kaplan–Meier estimates of mortality (1–survival).

<sup>d</sup>Cox Multivariate HR, adjusted for age group, sex and year of HF diagnosis.

<sup>e</sup>End of follow-up restricted to 1 year after second observed HF diagnosis.

<sup>f</sup>cumulative incidence function estimates of mortality (1–survival).

<sup>g</sup>Subdistribution HR, adjusted for age group, sex and year of HF diagnosis.

**Abbreviations:** CI, confidence interval; CVD, cardiovascular disease; HF, heart failure; HR, hazard ratio; SHR, sub-distribution hazard ratio.